Citi Global Healthcare Conference

Francis Cuss, MB BChir, FRCP Chief Scientific Officer

February 24, 2014

NOT FOR PRODUCT PROMOTIONAL USE 1 Forward-Looking Information

During this meeting, we will make statements about the Company’s future plans and prospects that constitute forward- looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

NOT FOR PRODUCT PROMOTIONAL USE 2 Evolution of BioPharma Strategy

Innovative Specialty Care Pharmaceuticals BioPharma

2007 2013

NOT FOR PRODUCT PROMOTIONAL USE 3 BMS R&D Focus

Disease Area Focus Drug Platforms

Immuno-Oncology

Oncology

Immunoscience Small Molecules Biologics Cardiovascular

Virology

Fibrotic Diseases

Exploratory Areas Antibody Drug Millamolecules Conjugates Metabolics *

* Focus on progressing early-development assets and transitioning late-stage assets to AstraZeneca NOT FOR PRODUCT PROMOTIONAL USE 4 Data as of Feb 1, 2014 BMY Development Portfolio by Disease Area

^ Marketed Product Phase I Phase II Phase III Development †

Eldelumab Anti-LAG3 Anti-CD28 YERVOY ® NULOJIX ® (Anti-IP10)

Denenicokin Anti-IL31 ® ® (IL-21) Elotuzumab SPRYCEL ELIQUIS

Lirilumab Factor XIa HIV Attachment NS5B Non Nuc ERBITUX® BARACLUDE® (Anti-KIR) Inhibitor Inhibitor

Urelumab IKur Inhibitor ® ® (Anti-CD137) NRT Inhibitor Daclatasvir ORENCIA REYATAZ

JAK2 Inhibitor PAR4 Antagonist HIV Program++ Asunaprevir

Peginterferon Notch Inhibitors Anti-PD-L1 LPA1 Antagonist lambda-1a

CCR2 / 5 (2) Anti-CXCR4 CCR2 / 5 (1) Antagonist Antagonist

Anti-CD40L PEG-FGF21 ^In Phase III development or currently under regulatory review ++ Mechanism of Action is not disclosed

IO ONC IMM CV † Approved in at least one major market (US, EU, JP, CN) VIR FD EA MET

NOT FOR PRODUCT PROMOTIONAL USE 5 2013 Pipeline Highlights

Cardiovascular  Submission of Eliquis VTE prevention and treatment Hepatitis C  Submission of daclatasvir and asunaprevir regimen in Japan (DUAL)  Submission of daclatasvir in the EU  Initiation of Phase III for the daclatasvir / asunaprevir / NS5B fixed dose combination tablet (Triple) Immuno-Oncology

 Nivolumab monotherapy and combination data at ASCO  Nivolumab lung data at WCLC  Progression and initiation of several potentially registrational trials  Yervoy pooled long-term survival data

NOT FOR PRODUCT PROMOTIONAL USE 6 Immuno-Oncology: Transformational Potential

 Yervoy: first agent to demonstrate long-term survival in some patients with metastatic melanoma

 Nivolumab: comprehensive development program – Multiple tumor types, histologies, and lines of therapy – Exploring the role of biomarkers – Monotherapy and combination

 Broad early stage portfolio

NOT FOR PRODUCT PROMOTIONAL USE 7 Data as of Feb 1, 2014 Immuno-Oncology – Development Portfolio Approved Phase I Phase II Registrational Indications

Urelumab (Anti-CD137) Elotuzumab* Elotuzumab* YERVOY ® YERVOY ® Cancer 2nd line MM 1st line MM Revlimid + Nivolumab* Unresectable or Velcade Combo Combo 1st line Melanoma Metastatic Melanoma Nivolumab* HCC Nivolumab* Elotuzumab* YERVOY ® Nivolumab* NHL (FL)^ Relapsed/Refractory Metastatic Melanoma Cancer (solid tumor) MM Revlimid Combo Dose Optimization Nivolumab* Nivolumab* NHL (DLBCL)^ Nivolumab* YERVOY ® Hematologic Mal. 2nd/3rd line RCC Adjuvant Melanoma YERVOY ® Anti-LAG3 + Gastric Nivolumab* YERVOY ® Nivolumab* 2nd line Sq NSCLC 1st line Sq NSCLC Cancer YERVOY ® + Ovarian Nivolumab* YERVOY ® Nivolumab* 2nd line NSq NSCLC Small Cell Lung Cancer (solid tumor) YERVOY ® Denenicokin + Adolescent melanoma Nivolumab* YERVOY ® Nivolumab* 3rd line Sq NSCLC Prostate (post- Nivolumab* + Cancer (solid tumor) hormonal therapy) YERVOY ® Nivolumab* Lirilumab + Glioblastoma^ 1st line Melanoma YERVOY ® Abbreviations Cancer (solid tumor) Nivolumab* CML: Chronic Myelogenous Leukemia Nivolumab* + 2nd/3rd line Melanoma DLBCL: Diffuse Large B-cell Lymphoma YERVOY ® FL: Follicular Lymphoma Cancer (solid tumor) Nivolumab* ^ HCC: Hepatocellular Carcinoma Nivolumab* + 1st line NSCLC Mal: Malignancy, Met: Metastatic YERVOY ® (PD-L1 +) MM: Multiple Myeloma Cancer (NSCLC) NHL: Non-Hodgkin Lymphoma Nivolumab* + * Development Partnership NSq: Non-Squamous, Sq: Squamous YERVOY ® Nivolumab: Ono Pharmaceuticals; Elotuzumab: AbbVie; NSCLC: Non Small Cell Lung Cancer Cancer (RCC) Lirilumab: Innate Pharma RCC: Renal Cell Carcinoma Nivolumab* + ^Published on ClinicalTrials.gov, not yet recruiting SPRYCEL® CML^ NOT FOR PRODUCT PROMOTIONAL USE 8 Key Data Flow & Events: 2014

 Potential approval in VTE treatment in the US and EU  Potential approval in VTE prevention in the US

 Potential approval of daclatasvir and asunaprevir in Japan (DUAL) Hepatitis C  Potential approval of daclatasvir in the EU Portfolio  Potential submission of daclatasvir and asunaprevir in the US

 Adjuvant melanoma data  Additional combination data with nivolumab

 Data from Phase II 3rd line squamous NSCLC  Phase I combinations in NSCLC and renal Nivolumab  Additional follow-up, including long term survival, from Phase I (Anti-PD1) monotherapy study in lung, renal and melanoma  Additional follow-up, including long tem survival, from Phase I combination study with in melanoma  Initiation of additional trials and in additional indications

Note: Dependent on data availability, acceptance of medical meeting submissions or health authority actions

NOT FOR PRODUCT PROMOTIONAL USE 9 Citi Global Healthcare Conference

Francis Cuss, MB BChir, FRCP Chief Scientific Officer

February 24, 2014

NOT FOR PRODUCT PROMOTIONAL USE 10